Mitochondria present in human cell is responsible for producing 90% of energy in body. Diseases caused by mutations of mitochondrial DNA are treated using mitochondrial-based therapeutics.
Mitochondrial dysfunction contributes many disorders like neurodegeneration, heart failure, metabolic disease or ischemic-reperfusion injury. Mitochondrial-based therapeutics includes mitochondria as a drug target for treatment of chronic, genetic and progressive diseases.
Mitochondrial dysfunction has symptoms like poor growth, muscle weakness, learning disabilities, increased risk of infection, respiratory problem and many more. According to the National Institute of Health (NIH), mitochondrial diseases is most common type of genetic disease with minimum prevalence of greater than 1 in 5000 people across the globe.
Covid-19 has led to a shift of focus for many biopharmaceutical companies to find coronavirus cure, delaying research and development activities in mitochondrial-based therapeutics market.
Manufacturing activities have been put on halt across various unit due to shut down leading reduced growth rate of mitochondrial-based therapeutics market. Reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities is impacting mitochondrial-based therapeutics market.
Rise in prevalence of mitochondrial disorders is expected to increase demand for mitochondrial-based therapeutics market. Increasing collaborative research and development activities among leading biopharmaceutical innovative players is expected to fuel the growth of mitochondrial-based therapeutics market.
For instance in June 2020 Reneo Pharmaceutical’s leading drug candidate REN001 was granted orphan drug designation by the U.S. Food and Drugs Administration for treatment of primary mitochondrial myopathy.
In addition clinical-stage development companies are allocating significant funds towards the development of mitochondrial-based therapeutics market. For instance in October 2019 Alexion Pharmaceuticals and Stealth Biotherapeutics Corp. announced their collaboration to co-develop and commercialize Elamipretide drug used as therapeutic for mitochondrial dysfunction.
Lack of awareness about therapeutic options available for mitochondrial dysfunction is expected to hinder mitochondrial-based therapeutics market growth. Stringent regulatory requirement for drug approval are challenging mitochondrial-based therapeutics market growth.
NSAIDs is expected to hold major revenue share of mitochondrial-based therapeutics market during forecast period. Mitochondrial myopathy created largest revenue share for mitochondrial-based therapeutics market. Leber’s heredity optic neuropathy and Leigh syndrome are forecast to generate significant revenue in mitochondrial-based therapeutics market.
Oral drugs are most commonly used in mitochondrial-based therapeutics market. Whereas hospital pharmacies is a largest distribution channel for mitochondrial-based therapeutics market. Online pharmacies is expected to observe significant growth rate in coming decade with increased rate of adoption.
North America will continue to dominate the mitochondrial-based therapeutics market in the coming decade with a high rate of approvals and commercialization of pharmaceutical drugs. The high rate of prevalence of mitochondrial dysfunctions increases the demand for mitochondrial-based therapeutics market in North America.
Europe is the second leading region in mitochondrial-based therapeutics market with increased investments towards research and development activities. Asia-pacific is lucrative with a higher growth rate in mitochondrial-based therapeutics market during the forecast period with a large patient population in the region.
The Middle East and Africa are expected to observe the least growth in mitochondrial-based therapeutics market due to less healthcare expenditure in the region.
Some key players contributing in mitochondrial-based therapeutics market are
- Pfizer Inc.
- Norvartis AG
- Takeda Pharmaceuticals
- Amgen Inc.
- NeuroVive Pharmaceutical AB
- Entogene AG
- Stealth Biotherapeutics
- Ixchel Pharma
- Reata Pharmaceuticals
- Khondrion BV
- Alkeus Pharmaceuticals
- Intercept Pharmaceutics
The report on mitochondrial-based therapeutics market covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Historical Actual Market Size 2015 - 2019
- Market Size & Forecast 2020 to 2030
- Supply & Demand Value Chain
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
- Market Drivers and Restraints
Regional analysis for mitochondrial-based therapeutics market includes
- North America
- Latin America
- East Asia
- South Asia
- Middle East & Africa
Report on mitochondrial-based therapeutics market highlights:
- Shifting industry dynamics
- In-depth market segmentation
- Historical current and projected industry size
- Recent industry trends
- Key competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
Mitochondrial-based Therapeutics Market: Segmentation
The global mitochondrial-based therapeutics market is classified based on drug type, indication, route of administration, distribution channel and region.
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Mitochondrial Myopathy
- Leber’s heredity Optic Neuropathy
- Leigh Syndrome
- Mitochondrial DNA Depletion Syndrome
- Mitochondrial Encephalomyopathy
- Lactic Acidosis
- Myoclonic Epilepsy with ragged red fibres
route of administration
- Hospital Pharmacies
- Retail Pharmacies
- Drug stores
- Online Pharmacies
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.